Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение стабильной ишемической болезни сердца

СПИСОК ЛИТЕРАТУРЫ

  1.  Sackett DL, Rosenberg WM, Gray JA et al. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312:71–72.
  2. 2. Федеральный закон от 21.11.2011 № 323-ФЗ (ред. от 03.04.2017) «Об основах охраны здоровья граждан в Российской Федерации». [Federal Law No. 323-FZ of November 21, 2011 (as amended on April 3, 2017) «On the Fundamentals of Health Protection of Citizens in the Russian Federation.» (in Russ.)]
  3. Эпидемиологический словарь: под ред. Джона М. Ласта для Между- народной эпидемиологической ассоциации. 4-е изд. М., 2009. 316 с. [Epidemiological Dictionary: ed. John M. Last for the International Epidemiological Association. 4th ed. M., 2009. 316 p. (in Russ.)]
  4. ГОСТР 52379-2005. Надлежащая клиническая практика. М.: Стандар- тинформ, 2005. 39 с. [GOST 52379-2005. Good Clinical Practice. M.: Standartinform, 2005. 39 p. (in Russ.)]
  5. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 03.07.2016) «Об об- ращении лекарственных средств». [Federal Law of 12.04.2010 No. 61-FZ (as amended on 03.07.2016) «On the Circulation of Medicines». (in Russ.)]
  6. Малая медицинская энциклопедия. М.: Медицинская энциклопе- дия, 1991—1996 гг. Режим доступа: http://dic.academic.ru/dic.nsf/ enc_medicine/28878/Синдром. [Small Medical Encyclopedia. M.: Medical encyclopedia, 1991-1996. Access mode: http://dic.academic.ru/dic.nsf/ enc_medicine/28878/ Syndrome. (in Russ.)]
  7. Руководство по кардиологии: под ред. акад. Е. И. Чазова. В 4 т. М.: Издательский дом «Практика», 2014. [Guide to Cardiology: ed. acad. E.
    1. Chazova. In 4 volumes. Moscow: Praktika Publishing House, 2014. (in Russ.)]
  8. Карпов Ю. А., Сорокин Е. В. Стабильная ишемическая болезнь сердца: стратегия и тактика лечения. 2-е изд., перераб. и доп. М.: Медицинское информационное агентство, 2012. 271 с. [Karpov Yu. A., Sorokin E.V. Stable coronary heart disease: strategy and tactics of treatment. 2nd ed., Rev. and add. Moscow: Medical Information Agency, 2012. 271 p. (in Russ.)]
  9. Карпов Ю. А., Кухарчук В. В., Лякишев А. и др. Диагностика и лечение хронической ишемической болезни сердца. Практические рекоменда- ции. Кардиологический вестник 2015; 3:3–33. [Karpov Yu. A., Kukharchuk VV, Lyakishev A. et al. Diagnosis and treatment of chronic ischemic heart disease. Practical guidelines. Cardiological Bulletin 2015; 3: 3–33. (in Russ.)]
  10. Кардиология: национальное руководство: под ред. Е. В. Шляхто. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 800 с. [Cardiology: national guidelines: ed. E. V. Shlyakhto. 2nd ed., Rev. and add. M .: GEOTAR-Media, 2015. 800 p. (in Russ.)]
  11. Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019 Aug 31; pii: ehz425. https:// doi.org/10.1093/eurheartj/ehz425
  12. Campeau L. Letter: Grading of angina pectoris. Circulation 1976; 54: 522– 523.
  13. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction. European Heart Journal. 2019Jan 14;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462
  14. Диагностика и лечение стабильной ишемической болезни сердца. Кли- нические рекомендации. М.; 2013. 69 с. [Diagnosis and treatment of stable coronary heart disease. Clinical guidelines. M.; 2013. p. 69. (in Russ.)]
  15. Международная классификация болезней МКБ-10. Режим доступа: http://www.mkb10.ru [15. International classification of diseases ICD-10. Access mode: http://www.mkb10.ru (in Russ.)]
  16. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med. 1979;300:1350–1358.
  17. Genders TS, Steyerberg EW, Alkadhi H, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart. J 2011;32:1316–1330.
  18. Foldyna B, Udelson JE, Karady J et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond- Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging. 2018;20:574–581. https:// doi.org/10.1093/ehjci/jey182
  19. Adamson PD, Newby DE, Hill CL, et al. Comparison of international guidelines for assessment of suspected stable angina: insights from the PROMISE and SCOT-HEART. JACC Cardiovasc Imaging. 2018;11:1301–1310. https://doi. org/10.1016/j.jcmg.2018.06.021
  20. Montalescot G, SechtemU, Achenbach Set al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable Coronary artery disease of European Society of Cardiology. EurHeartJ 2013; 34, 2949–3003.
  21. Арутюнов Г. П., Бойцов С. А., Воевода М. И. и др. Коррекция гипертри- глицеридемии с целью снижения остаточного риска при заболеваниях, вызванных атеросклерозом. Заключение Совета экспертов. Российский кардиологический журнал. 2019; 9:44–51. [Arutyunov G. P., Boytsov S. A., Voevoda M. I. et al. Correction of hypertriglyceridemia in order to reduce the residual risk in diseases caused by atherosclerosis. Conclusion of the Council of Experts. Russian journal of cardiology. 2019; 9: 44-51 (in Russ.)]. https:// doi.org/10.15829 / 1560-4071-2019-9-44-51
  22. Piepoli MF, Hoes AW, StefanAgewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal. 2016 Aug 1;37(29):2315–2381. https://doi.org/10. 1093/eurheart/ ehw106
  23. Кухарчук В. В., Коновалов Г. А., Сусеков А. В. и др. Диагностика и кор- рекция нарушений липидного обмена с целью профилактики и лече- ния атеросклероза. Российские рекомендации, VI пересмотр. М., 2017. 44 с. [Kukharchuk V. V., Konovalov G. A., Susekov A. V. et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VI revision. M., 2017. p. 44. (in Russ.)]
  24. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272
  25. Cohn P.F., Fox K.M., Daly C. Silent myocardial ischemia. Circulation 2003;108:1263-1277.
  26. Androulakis A., Aznaouridis K.A., Aggeli C.J., Roussakis G.N., Michaelides A.P., Kartalis A.N., Stougiannos P.N., Dilaveris P.E., Misovoulos P.I., Stefanadis C.I., Kallikazaros I.E. Transient ST-segment depression during paroxysms of atrial fibrillation in otherwise normal individuals: relation with underlying coronary artery disease. J Am Coll Cardiol 2007;50:1909-1911
  27. Steeds R.P., Garbi M., Cardim N. et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017;18:1191– 1204. https://doi.org/10.1093/ehjci/jew333
  28. Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina — results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262–267.
  29. Smedsrud M.K., Gravning J., Omland T., et al. Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain. Int J Cardiovasc Imaging. 2015;31:967–973. https://doi.org/10.1007/ s10554-015-0646-6
  30. Senior R, Becher H, Monaghan M et al. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. EurHeartJCardiovascImaging 2017;18: 1205–1205af. https://doi.org/10.1093/ehjci/jex182
  31. Thomson H.L., Basmadjian A.J., Rainbird A.J., Razavi M., Avierinos J.F., Pellikka P.A. et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. J Am Coll Cardiol 2001;38:867–875
  32. Greenwood JP, Ripley DP, Berry C, et al. Effect of care guided by cardiovascular magnetic resonance, myocardial perfusion scintigraphy, or NICE guidelines on subsequent unnecessary angiography rates: the CE-MARC 2 randomized clinical trial. JAMA. 2016;316:1051–1060.
  33. Boogers MJ, Broersen A, Van Velzen JE et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. Eur. Heart J. 2012; 33 (8): 1007–1016.
  34. Touboul P.J., Hennerici M.G., Meairs S., Adams H., Amarenco P., Desvarieux M., Ebrahim S., Fatar M., Hernandez H.R, Kownator S., Prati P., Rundek T., Taylor A., Bornstein N., Csiba L., Vicaut E., Woo K.S., Zannad F., Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004;18:346–349
  35. Vlachopoulos C., Xaplanteris P., Aboyans V., Brodmann M., Cifkova R., Cosentino F., et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 2015;241:507–532
  36. Forslund L, Hjemdahl P, Held C, Bjorkander I, Eriksson SV, Rehnqvist N. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. Eur Heart J. 1998;19:578–587.
  37. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 1997;95:2037–2043.
  38. Stone PH, Chaitman BR, Forman S, et al. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol. 1997;80:1395–1401.
  39. Versteylen M.O., Joosen I.A., Shaw L.J., Narula J., Hofstra L. Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events. J Nucl Cardiol. 2011;18:904–911.
  40. Fordyce C.B., Douglas P.S., Roberts R.S. et al. Identification of patients with stable chest pain deriving minimal value from noninvasive testing: the PROMISE minimal-risk tool, a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2017;2:400–408. https://doi.org/10.1001/ jamacardio.2016.5501
  41. Jensen J.M., Voss M., Hansen V.B. et al. Risk stratification of patients suspected of coronary artery disease: comparison of five different models. Atherosclerosis. 2012;220:557–562.
  42. Budoff M.J., Mayrhofer T., Ferencik M. et al. Prognostic value of coronary artery calcium in the PROMISE study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;136:1993–2005. https://doi. org/10.1161/CIRCULATIONAHA.117.030578
  43. Reeh J., Therming C.B., Heitmann M. et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. Eur Heart J. 2018;40:1426–1435. https://doi.org/10.1093/eurheartj/ehy806
  44. Karthikeyan G, Guzic Salobir B, Jug B et al. Functional compared to anatomical imaging in the initial evaluation of patients with suspected coronary artery disease: an international, multi-center, randomized controlled trial (IAEA-SPECT/CTA study). J Nucl Cardiol. 2017;24:507–517. https://doi. org/10.1007/s12350-016-0664-3
  45. Hoffmann U, Ferencik M, Udelson JE et al. Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;135:2320–2332. https://doi.org/10.1161/ CIRCULATIONAHA.116.024360
  46. Siontis GC, Mavridis D, Greenwood JP, et al. Outcomes of non-invasive diagnostic modalities for the detection of coronary artery disease: network meta-analysis of diagnostic randomised controlled trials. BMJ. 2018;360:k504. https://doi.org/10.1136/bmj.k504
  47. Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. Eur Heart J. 2018;39:3322–3330.
  48. Zacharias K, Ahmed A, Shah BN, et al. Relative clinical and economic impact of exercise echocardiography vs. exercise electrocardiography, as first line investigation in patients without known coronary artery disease and new stable angina: a randomized prospective study. Eur Heart J Cardiovasc Imaging. 2017;18:195–202. https://doi.org/10.1093/ehjci/jew049
  49. Williams MC, Hunter A, Shah ASV, et al. Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol. 2016;67:1759–1768. https://doi.org/10.1016/j. jacc.2016.02.026
  50. Knuuti J, Bengel F, Bax JJ et al. Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease. Eur Heart J. 2014;35:633–638.
  51. Jorgensen ME, Andersson C, Norgaard BL, et al. Functional testing or coronary computed tomography angiography in patients with stable coronary artery disease. J AmColl Cardiol. 2017;69:1761–1770. https://doi. org/10.1016/j.jacc.2017.01.046
  52. Roifman I, Wijeysundera HC, Austin PC, et al. Comparison of anatomic and clinical outcomes in patients undergoing alternative initial noninvasive testing strategies for the diagnosis of stable coronary artery disease. J Am Heart Assoc. 2017;6:e005462. https://doi.org/10.1161/JAHA.116.005462
  53. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012–1024.
  54. Shaw L.J., Berman D.S., Picard M.H., Friedrich M.G., Kwong R.Y., Stone G.W. et al; National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored ISCHEMIA Trial Investigators. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC CardiovascImaging 2014;7:593-604.
  55. Johnson NP, Toth GG, Lai D et al. Prognostic value of fractional flow reserve: linking physiologic severity to clinical outcomes. J Am Coll Cardiol. 2014;64:1641–1654.
  56. Barbato E, Toth GG, Johnson NP, et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. J Am Coll Cardiol. 2016;68:2247–2255. https://doi.org/10.1016/j.jacc.2016.08.055
  57. Меркулов Е. В., Миронов В. М., Самко А. Н. Коронарная ангиография, вентрикулография, шунтография. В иллюстрациях и схемах. М.: Медиа- Медика, 2011. 100 с. [Merkulov E. V., Mironov V. M., Samko A. N. Coronary angiography, ventriculography, shuntography. In illustrations and diagrams. M.: Media-Medica, 2011. p. 100 (in Russ.)]
  58. Zimmermann FM, Omerovic E, Fournier S et al. Fractional flow reserve- guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019 Jan 7;40(2):180–186. https://doi.org/10.1093/eurheartj/ ehy812
  59. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser GC, Alderman E, Killip T III. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645 2657
  60. DeBruyne B, Pijls NH, Kalesan B et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.
  61. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA, Van’t Veer M, Pijls NH. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816-2821
  62. Миронов В. М., Меркулов Е. В., Терещенко А. С., Самко А. Н., Соло- мянный В. В., Тагиева Н. Р., Сергиенко И. В., Карпов Ю. А. Измерение фракционного резерва кровотока для выбора тактики лечения пациен- тов с многососудистым и многоуровневым поражением коронарного русла. Атеросклероз и дислипидемии, 2014. №2(15) с.17-22 [Mironov V.M., Merkulov E.V., Tereshchenko A.S., Samko A.N., Solomyanny V.V., Tagieva N.R., Sergienko I.V., Karpov Yu. A. Measurement fractional blood flow reserve for the choice of treatment tactics in patients with multivessel and multilevel coronary lesions. Atherosclerosis and dyslipidemia, 2014. No. 2 (15) p.17-22 (in Russ.)]
  63. Ng A.C.T., Prihadi E.A., Antoni M.L. et al. Left ventricular global longitudinal strain is predictive of all-cause mortality independent of aortic stenosis severity and ejection fraction. Eur Heart J Cardiovasc Imaging. 2018;19:859– 867. https://doi.org/10.1093/ehjci/jex189
  64. Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular dysfunction among patients with chest pain and nonobstructive coronary artery disease. JACC Cardiovasc Interv. 2015;8:1445–1453.
  65. Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131:1054–1060.
  66. Ong P, Athanasiadis A, Borgulya G et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129:1723–1730.
  67. Schoenenberger AW, Adler E, Gujer S et al. Prognostic value of an abnormal response to acetylcholine in patients with angina and non-obstructive coronary artery disease: long-term follow-up of the Heart Quest cohort. Int J Cardiol. 2016;221:539–545. https://doi.org/10.1016/j.ijcard.2016.07.035
  68. Aziz A, Hansen HS, Sechtem U, Prescott E, Ong P. Sex-related differences in vasomotor function in patients with angina and unobstructed coronary arteries. J Am Coll Cardiol. 2017;70:2349–2358. https://doi.org/10.1016/j. jacc.2017.09.016
  69. Beltrame JF, Crea F, Kaski JC et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017;38:2565–2568. https://doi. org/10.1093/eurheartj/ehv351
  70. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014;78:2779–2801.
  71. Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72:2841–2855.
  72. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791.
  73. Kass M, Allan R, Haddad H. Diagnosis of graft coronary artery disease. Curr Opin Cardiol.2007; 22:139–145.
  74. Baris N, Sipahi I, Kapadia SR, et al. Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade. J Heart Lung Transplant.2007;26:593–597.
  75. Zimmer RJ, Lee MS. Transplant coronary artery disease. JACC Cardiovasc Interv. 2010;3:367–377.
  76. D’Ascenzo F, Barbero U, Cerrato E, et al. Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: a meta-analysis of 2,581 patients and 2,807 lesions. Am Heart J. 2015;169 (5):663–673. https://doi. org/10.1016/j.ahj.2015.01.013
  77. Waksman R, Legutko J, Singh J et al. FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. J Am Coll Cardiol. 2013;61:917– 923.
  78. Park SJ, Ahn JM, Kang SJ, et al. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. JACC Cardiovasc Interv. 2014;7:868–874.
  79. Ben-Dor I, Torguson R, Deksissa T et al. Intravascular ultrasound lumen area parameters for assessment of physiological ischemia by fractional flow reserve in intermediate coronary artery stenosis. Cardiovasc Revasc Med. 2012 May-Jun;13(3):177–82.
  80. Mark DB, Shaw L, Harrell FE Jr, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325:849–853.
  81. Maaniitty T, Stenstrom I, Bax JJ et al. Prognostic value of coronary CT angiography with selective PET perfusion imaging in coronary artery disease. JACC Cardiovasc Imaging. 2017;10:1361–1370. https://doi.org/10.1016/j. jcmg.2016.10.025
  82. SCOT-HEART investigators. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open- label, parallel-group, multicentre trial. Lancet. 2015;385:2383–2391.
  83. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339
  84. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
  85. Xie X, Atkins E, Lv J, Bennett A et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443. https://doi.org/10.1016/ S0140-6736(15)00805-3
  86. Артериальная гипертензия у взрослых. Клинические рекоменда- ции 2020. Российский кардиологический журнал. 2020;25(3):3786. [Arterial hypertension in adults. Clinical guidelines 2020. Russian journal of cardiology. 2020; 25 (3): 3786. (in Russ.)] https://doi.org/10.15829 /1560- 4071-2020-3-3786
  87. Сахарный диабет 2 типа у взрослых. Клинические рекомендации 2019. Сахарный диабет. 2020;23(S2). [Diabetes mellitus type 2 in adults. Clinical guidelines 2019. Diabetes mellitus. 2020; 23 (S2). (in Russ.)] https://doi. org/10.14341/dm23s2
  88. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J (2020) 41, 255-323. https://doi.org/10.1093/eurheartj/ehz486
  89. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, et al. Aspirin 3567 in the primary and secondary prevention of vascular disease: collaborative meta-analysis of 3568 individual participant data from randomized trials. Lancet. 2009;373:1849–1860. https://doi.org/10.1016/ S0140-6736(09)60503-1
  90. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348:1329–1339. https://doi.org/10.1016/s0140-6736(96)09457-3
  91. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:21552166
  92. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:919.
  93. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, LopezJaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:13191330
  94. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:17911800.
  95. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, WebbPeploe M, Van Belle E, McFadden EP. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation 1998;98:1597–1603.
  96. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126–2132.
  97. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213260
  98. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010 Feb;9(2):154-69. https://doi.org/10.1038/ nrd2957
  99. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019;380:15091524.
  100. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:15131524.
  101. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:24232434.
  102. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:20932104.
  103. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:28932962.
  104. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969974
  105. Renato D. Lopes, MD, PhD1; Sergio Leonardi, MD, MHS2; Daniel M. Wojdyla, MS1; Amit N. Vora, MD, MPH3; Laine Thomas, PhD1; Robert F. Storey, BSc, BM, DM4; Dragos Vinereanu, MD, PhD5; Christopher B. Granger, MD1; Shaun G. Goodman, MD, MSc6; Ronald Aronson, MD7; Stephan Windecker, MD8; Holger Thiele, MD9; Marco Valgimigli, MD, PhD8; Roxana Mehran, MD10; John H. Alexander, MD, MHS1 Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. https://doi.org/10.1161/circulationaha.119.044584
  106. Hindricks G., Potpara T., Dagres N., Arbelo E. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2020) 42, 373-498. https://doi.org/10.1093/eurheartj/ehaa612
  107. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med. 2010; 363: 1909–1917. https://doi. org/10.1056/NEJMoa1007964
  108. Kwok C, Shing, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: Meta-analysis. Int J Cardiol. 2012; 167: 965–974.
  109. Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J. Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients with Coronary Artery Disease: A Systematic Review and Meta- Analysis. Archives of Medical Research. 2012; 43: 212–224.
  110. Melloni C, Washam JB, Jones WS et al. Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy. Systematic Review. CircCardiovascQual Outcomes. 2015; 8: 47–55. https://doi.org/10.1161/CIRCOUTCOMES.114.001177
  111. Sehested TSG, Carlson N, Hansen PW, et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019; 40: 1963–1970. https://doi.org/10.1093/eurheartj/ehz104
  112. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 Aug 31; pii: ehz455. https://doi.org/10.1093/eurheartj/ ehz455
  113. Murphy SA, Pedersen TR, Gaciong ZA et al. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 Jul 1;4(7):613–619. https://doi.org/10.1001/jamacardio.2019.0886
  114. Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73:387–396. https://doi.org/10.1016/j.jacc.2018.10.039
  115. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
  116. Rossignol P, Girerd N, Bakris G et al. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017;19:792–799. https://doi.org/10.1002/ejhf.688
  117. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
  118. Pauly DF, Johnson BD, Anderson RD et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678684.
  119. Ong P, Athanasiadis A, Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. Eur Heart J Cardiovasc Pharmacother. 2015;1:6571.
  120. Crea F, Lanza G. Treatment of microvascular angina: the need for precision medicine. European Heart Journal. (2016) 37, 1514–1516. https://doi. org/10.1093/eurheartj/ehw021
  121. Buxton A, Goldberg S, Hirshfeld JW, et al. Refractory ergonovine-induced coronary vasospasm: importance of intracoronary nitroglycerin. Am J Cardiol. 1980;46:329334.
  122. Сергиенко В. Б., Самойленко Е., Саютина Е. В. и др. Роль дисфункции эндотелия в развитии ишемии миокарда у больных ИБС с неизменен- ными и малоизмененными коронарными артериями. Кардиология. 1999; 1:25–30. [Sergienko VB, Samoilenko E., Sayutina EV, et al. The role of endothelial dysfunction in the development of myocardial ischemia in patients with coronary artery disease with unchanged and slightly altered coronary arteries. Cardiology. 1999; 1: 25-30. (in Russ.)]
  123. Tsuburaya R, Takahashi J, Nakamura A et al. Beneficial effects of long acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: the NOVEL study. Eur Heart J. 2016;37:27132721.
  124. Boden WE, O’Rourke RA, Teo KK et al.; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503–1516.
  125. BARI Study Group 2D, Frye RL, August P et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515.
  126. Hueb W, Lopes N, Gersh BJ et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010;122:949–957.
  127. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563–570.
  128. Bittl JA, He Y, Jacobs AK et al. American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 2013;127:2177–2185.
  129. Dzavik V, Ghali WA, Norris C, Mitchell LB, Koshal A, Saunders LD, Galbraith PD, Hui W, Faris P, Knudtson ML, Alberta for Provincial Project in Outcome Assessment Coronary Heart Disease Investigators. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: A report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J 2001;142:119–126.
  130. Lee PH, Ahn JM, Chang M, Baek S, Yoon SH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Left main coronary artery disease: Secular trends in patient characteristics, treatments, and outcomes. J Am Coll Cardiol 2016;68:1233–1246.
  131. Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, Lilly RE, Sketch MH Jr, Peterson ED, Jones RH. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006;82: 1420–1428; discussion 1428–1429.
  132. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, Higgins RS, Carlson RE, Jones RH. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med 2008;358:331–341.
  133. Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, Stamato NJ, Gold JP, Sharma S, Venditti FJ, Powell T, King SB III. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation 2012;125:1870–1879.
  134. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, Taylor HA, Chaitman BR. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995;91:2335–2344.
  135. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009;120:2529–2540.
  136. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985;312:1665–1671.
  137. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O’Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607– 1616.
  138. Jones RH, Kesler K, Phillips HR III, Mark DB, Smith PK, Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111:1013–1025.
  139. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528–1534.
  140. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, Michler RE, Bonow RO, Doenst T, Petrie MC, Oh JK, She L, Moore VL, Desvigne- Nickens P, Sopko G, Rouleau JL; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511–1520.
  141. Panza JA, Velazquez EJ, She L, Smith PK, Nicolau JC, Favaloro RR, Gradinac S, Chrzanowski L, Prabhakaran D, Howlett JG, Jasinski M, Hill JA, Szwed H, Larbalestier R, Desvigne-Nickens P, Jones RH, Lee KL, Rouleau JL. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 2014;64:553–561.
  142. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ, STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: An analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016;134:1314–1324.
  143. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117(10):1283–1291.
  144. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900–2907.
  145. Gada H, Kirtane AJ, Kereiakes DJ, Bangalore S, Moses JW, Genereux P, Mehran R, Dangas GD, Leon MB, Stone GW. Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia. Am J Cardiol 2015;115:1194–1199.
  146. Stergiopoulos K, Boden WE, Hartigan P, Mobius-Winkler S, Hambrecht R, Hueb W, Hardison RM, Abbott JD, Brown DL. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clin- ical trials. JAMA Intern Med 2014;174:232– 240.
  147. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H; Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008;1:469–479.
  148. Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, Keeble T, Mielewczik M, Kaprielian R, Malik IS, Nijjer SS, Petraco R, Cook C, Ahmad Y, Howard J, Baker C, Sharp A, Gerber R, Talwar S, Assomull R, Mayet J, Wensel R, Collier D, Shun-Shin M, Thom SA, Davies JE, Francis DP, ORBITA Investigators. Percutaneous coronary intervention in stable angina (ORBITA): A double-blind, randomised controlled trial. Lancet 2018;391:31–40
  149. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation 2005;111:2906–2912.
  150. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta- analysis of 17 randomized trials of a percutaneous coronary intervention- based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:894–904.
  151. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911–918.
  152. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 2013;127:769–781.
  153. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: A systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv 2012;5:476–490.
  154. Thomas S, Gokhale R, Boden WE, Devereaux PJ. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 2013;29:472– 482.
  155. DeBruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nuesch E, Juni P; FAME-2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 2014;371:1208–1217.
  156. Миронов В. М., Меркулов Е. В., Самко А. Н. Оценка фракционного резерва кровотока. Кардиология. 2012; 52(8):46–56. [Mironov VM, Merkulov EV, Samko AN Assessment of the fractional reserve of blood flow. Cardiology. 2012; 52 (8): 46-56. (in Russ.)]
  157. Witberg G, Regev E, Chen S et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:1428–1435.
  158. Chakravarty T, Sharma R, Abramowitz Y, et al. Outcomes in patients with transcatheter aortic valve replacement and left main stenting: the TAVR-LM registry. J Am Coll Cardiol. 2016;67:951–960.
  159. Kaikita K, Ogawa H. [Guidelines for Diagnosis and Treatment of Patients with Vasospastic Angina (Coronary Spastic Angina) (Revised Version 2013). Nihon Rinsho. 2016 Aug;74 Suppl 6:54-7. Japanese. PubMed PMID: 30540370.
  160. Tanabe Y, Itoh E, Suzuki K, Ito M, Hosaka Y, Nakagawa I, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. J Am Coll Cardiol 2002; 39:1120-1126.
  161. Corcos T, David PR, Bourassa MG, Val PG, Robert J, Mata LA, et al. Percutaneous transluminal coronary angioplasty for the treatment of variant angina. J Am Coll Cardiol 1985; 5: 1046 – 1054.
  162. Bertrand ME, LaBlanche JM, Thieuleux FA, Fourrier JL, Traisnel G, Asseman P. Comparative results of percutaneous transluminal coronary angioplasty in patients. J Am Coll Cardiol 1986; 8: 504 – 508.
  163. Prinzmetal M, Ekmekci A, Kennamer R, Kwoczynski JK, Shubin H, Toyoshima H. Variantform of angina pectoris, previously undelineated syndrome. JAMA 1960; 174: 1794 – 1800.
  164. MacAlpin RN. Relation of coronary arterial spasm to sites of organic stenosis. Am J Cardiol 1980; 46: 143 – 153.
  165. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122:152–161.
  166. Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007;334:617.
  167. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, McDonald KM, Owens DK, Hlatky MA, Bravata DM. Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. JACC Cardiovasc Interv 2008;1:483–491.
  168. Blazek S, Holzhey D, Jungert C, Borger MA, Fuernau G, Desch S, Eitel I, de Waha S, Lurz P, Schuler G, Mohr FW, Thiele H. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. JACC Cardiovasc Interv 2013;6:20–26.
  169. Hannan EL, Zhong Y, Walford G, Holmes DR Jr, Venditti FJ, Berger PB, Jacobs AK, Stamato NJ, Curtis JP, Sharma S, King SB III. Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. J Am Coll Cardiol 2014;64:2717– 2126.
  170. Blazek S, Rossbach C, Borger MA, Fuernau G, Desch S, Eitel I, Stiermaier T, Lurz P, Holzhey D, Schuler G, Mohr FW, Thiele H. Comparison of sirolimus- eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial. JACC Cardiovasc Interv 2015;8:30–38.
  171. Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, Schuler G, Falk V. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. J Am Coll Cardiol 2009;53:2324–2331.
  172. Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: A meta-analysis of randomized clinical data. J Am Coll Cardiol 2011;58:1426–1432.
  173. Giacoppo D, Colleran R, Cassese S, Frangieh AH, Wiebe J, Joner M, Schunkert H, Kastrati A, Byrne RA. Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: A systematic review and meta-analysis. JAMA Cardiol 2017;2:1079–1088.
  174. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators S. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery dis- ease. N Engl J Med 2009;360:961–972.
  175. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Choo SJ, Chung CH, Lee JW, Cohen DJ, Yeung AC, Hur SH, Seung KB, Ahn TH, Kwon HM, Lim DS, Rha SW, Jeong MH, Lee BK, Tresukosol D, Fu GS, Ong TK; BEST Trial Investigators. Trial of everolimus- eluting stents or bypass surgery for coronary disease. N Engl J Med 2015;372:1204–1212.
  176. Chang M, Ahn JM, Lee CW, Cavalcante R, Sotomi Y, Onuma Y, Tenekecioglu E, Han M, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Serruys PW, Park SJ. Long-term mortality after coronary revascularization in nondiabetic patients with multivessel disease. J Am Coll Cardiol 2016;68:29–36
  177. Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three- vessel disease: Final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821–2830.
  178. Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: Comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc 2013;2:e000354.
  179. Herbison P, Wong CK. Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta- regression. BMJ Open 2015;5:e010055.
  180. Kamalesh M, Sharp TG, Tang XC, Shunk K, Ward HB, Walsh J, King S III, Colling C, Moritz T, Stroupe K, Reda D; CARDS Investigators VA. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 2013;61:808–816.
  181. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ, Investigators S. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013;43:1006–1013.
  182. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in dia- betic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010;55:432–440.
  183. Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, Silber S, Serruys PW, Pilgrim T, Raber L, Heg D, Juni P, Windecker S. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: Patient-level pooled analysis of 6081 patients. Circ Cardiovasc Interv 2016;9:e003255.
  184. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: Network meta-analysis. BMJ. 2014;348:g3859.
  185. Bonaa KH, Mannsverk J, Wiseth R et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–1252.
  186. Palmerini T, Benedetto U, Biondi-Zoccai G et al. Long-term safety of drug- eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–2507.
  187. Stefanini GG, Byrne RA, Windecker S. State of the art : coronary artery stent — past, present and future. EuroIntervention. 2017;13(6):706–716. https:// doi.org/10.4244/EIJ-D-17-00557
  188. Sabate M, Windecker S, Iniguez A et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229–240. https://doi.org/10.1093/eurheartj/ehv500
  189. Cassese S, Byrne RA, Ndrepepa G et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: A meta-analysis of randomized controlled trials. Lancet. 2016;387:537–544. https://doi. org/10.1016/S0140-6736(15)00979-4
  190. Cassese S, Byrne RA, Juni P, et al. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: A meta-analysis of randomized trials. EuroIntervention. 2018;13:1565–1573. https://doi. org/10.4244/EIJ-D-17-00492
  191. Valgimigli M, Gagnor A, Calabro P et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomized multicentre trial. Lancet. 2015;385:2465—2476. https://doi. org/10.1016/S0140-6736(15)60292-6
  192. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): A randomized, parallel group, multicentre trial. Lancet. 2011;377:1409–1420.
  193. Ferrante G, Rao SV, Juni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: A meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016;9:1419–1434. https://doi.org/10.1016/j.jcin.2016.04.014
  194. Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87–165. https:// doi.org/10.1093/eurheartj/ehy394
  195. Gaudino M, Angelini G D, Antoniades C et al. Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate. J Am Heart Assoc. 2018;7(16):e009934. https://doi.org/10.1161/JAHA.118.009934
  196. Melby SJ, Saint LL, Balsara K et al. Complete coronary revascularization improves survival in octogenarians. Ann Thorac Surg. 2016;102:505–511.
  197. Taggart DP, Altman DG, Gray AM et al. Randomized trial of bilateral versus single internal-thoracic-artery grafts. N Engl J Med. 2016;375:2540–2549. https://doi.org/10.1056/NEJMoa1610021
  198. Gaudino M, Tranbaugh R, Fremes S. Bilateral versus single internal thoracic artery grafts. N Engl J Med. 2017;376:e37. https://doi.org/10.1056/ NEJMc1703358
  199. Gaudino M, Benedetto U, Fremes S, et al. Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery. N Engl J Med. 2018; 378:2069– 2077. https://doi.org/10.1056/NEJMoa1716026
  200. Arora RR, Chou TM, Jain D, et al. Effects of enhanced external counter pulsation on Health-Related Quality of Life continue 12 months after treatment: a sub study of the Multicenter Study of Enhanced External Counter pulsation. J Investig Med. 2002;50:25–32.
  201. Zipes DP, Svorkdal N, Berman D, et al. Spinal cord stimulation therapy for patients with refractory angina who are not candidates for revascularization. Neuromodulation. 2012;15:550–558.
  202. Henry TD, Losordo DW, Traverse JH et al. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018;39:2208–2216.
  203. Briones E, Lacalle JR, Marin-Leon I, Rueda JR. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2015;2:CD003712.
  204. Mohr F. W., Morice M.-C., Kappetein A. P., Feldman T. E. et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381(9867):629-38. https://doi.org/10.1016/S0140-6736(13)60141-5
  205. Ducrocq G., Wallace J. S., Baron G., Ravaud P. et al. REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010; 31: 1257–1265. https://doi. org/10.1093/eurheartj/ehq021

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

СПИСОК ЛИТЕРАТУРЫ
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*